SCIENCEDOMAIN *international*
www.sciencedomain.org

SDI Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	**Ms_JPRI_49489**
Title of the Manuscript:	**Potentiation of Cisplatin Activity in Colorectal Cancer Cells by Lovastatin**
Type of the Article	**Original Research Article**

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty'**, provided the manuscript is scientifically robust and technically sound.
To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline)

PART 1: Review Comments

	Reviewer's comment	**Author's comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*
Compulsory REVISION comments	**This manuscript is full of spelling, grammar, formatting, and punctuation errors. Even the most minimal review function of a word processing program would have identified and corrected most of the errors.** **The authors state that "The major regimen for cancer treatment is chemotherapy." Well, that depends on the cancer. The paper is about colorectal cancer cells, so for that disease, when it is in the primary stage, the major treatment regimen is surgical resection. Chemotherapy may be added secondarily, and of course for metastatic cancer, then chemotherapy is primary. The authors are using the HCT-116 cell line. How do they think that cell line was isolated? It was isolated from a surgically resected carcinoma. That sentence should be rewritten.** **Standard deviation (SD) should be used for the error bars, not standard error of the mean (SEM). In addition, the Materials and Methods should state what P level is considered statistically significant.** **It may be interesting to test Lovastatin in an *APC* mutant colorectal cancer cell line (HCT-116 is *APC* wild-type and *beta-catenin* mutant), considering the utility of TASIN-1 against *APC* mutant cell lines through a mechanism involving cholesterol synthesis. That is mot a required revision, but it may be something to consider for the future and possibly include as point in the Discussion.**	
Minor REVISION comments		
Optional/General comments		

SDI Review Form 1.6

PART 2:

	Reviewer's comment	**Author's comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*
Are there ethical issues in this manuscript?	*(If yes, Kindly please write down the ethical issues here in details)*	

Reviewer Details:

Name:	***Michael Bordonaro***
Department, University & Country	***Medical Education, Geisinger Commonwealth School of Medicine, USA***